Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.
After a stellar FQ4 earnings show from RHT, Christopher Eberle now calls for 14% in return potential for the stock.
Ruben Roy now calls for 20% in return potential for MU shares.
Canaccord’s Mark Massaro now bets on 50% in return potential for the healthcare player.
Mizuho’s Difei Yang approaches the biotech player as a new bull, angling for a whopping 204% in return potential for MRNS shares.
RBC Capital’s Mitch Steves now spotlights 14% in return potential for NVDA shares.
Yet another analyst has weighed in on Nutanix Inc (NASDAQ:NTNX) and pushed sales forecast higher for the hyper-converged infrastructure maker. Maxim analyst Nehal Chokshi reiterated a Buy …
The medical device maker scores a bullish analyst nod.
BTIG’s Edward Parker does not want to miss out any more on NTNX’s rapid-fire momentum, opting to join the bullish camp.
Cantor’s Elemer Piros bets on 52% upside potential for DVAX stock following its 2017 performance.
